Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on 01753 627777.
Importance of cabozantinib + nivolumab for the treatment of aRCC
Renal Cell Carcinoma
Video
05:40
Hear from Prof. Laurence Albiges and Prof. James Larkin on the importance of cabo+nivo for the treatment of aRCC.
CBZ-UK-000341 | November 2024
